APA (7th ed.) Citation

Schlotawa, L., Tyka, K., Kettwig, M., Ahrens‐Nicklas, R. C., Baud, M., Berulava, T., . . . Gärtner, J. (2023). Drug screening identifies tazarotene and bexarotene as therapeutic agents in multiple sulfatase deficiency. EMBO Molecular Medicine, 15(3), . https://doi.org/10.15252/emmm.202114837

Chicago Style (17th ed.) Citation

Schlotawa, Lars, et al. "Drug Screening Identifies Tazarotene and Bexarotene as Therapeutic Agents in Multiple Sulfatase Deficiency." EMBO Molecular Medicine 15, no. 3 (2023). https://doi.org/10.15252/emmm.202114837.

MLA (9th ed.) Citation

Schlotawa, Lars, et al. "Drug Screening Identifies Tazarotene and Bexarotene as Therapeutic Agents in Multiple Sulfatase Deficiency." EMBO Molecular Medicine, vol. 15, no. 3, 2023, https://doi.org/10.15252/emmm.202114837.